Introduction
============

Bacterial infections caused by MDR Gram-negative pathogens, including ESBL-producing and carbapenem-resistant Enterobacteriaceae (CRE), are increasing in prevalence and represent a serious threat to public health.[@dkz497-B1]^,^[@dkz497-B2] Strains that express MBLs are of particular concern as coexpression of serine β-lactamases and other drug resistance determinants means these strains are often resistant to a range of antibiotics,[@dkz497-B3] resulting in a lack of effective treatment options and a high level of unmet need.

Complicated intra-abdominal infections (cIAIs) are polymicrobial in nature, with pathogens frequently including Enterobacteriaceae, particularly *Escherichia coli* and *Klebsiella* spp.; those less frequently isolated include obligate and facultative anaerobes and Gram-positive cocci.[@dkz497-B6] cIAIs are an important cause of morbidity and mortality, particularly if not adequately managed.[@dkz497-B10]^,^[@dkz497-B11]

The monobactam aztreonam has a well-established safety and efficacy profile and is licensed for the treatment of various serious infections caused by susceptible Gram-negative bacteria.[@dkz497-B12] Aztreonam has activity against MBL-producing pathogens, but can be hydrolysed and rendered inactive by most Ambler Class A, C and D serine β-lactamases.[@dkz497-B13]^,^[@dkz497-B14] Avibactam is a broad-spectrum non-β-lactam β-lactamase inhibitor that inhibits Ambler class A, C and some D β-lactamases.[@dkz497-B15]

The combination of ceftazidime with avibactam is approved in the USA and Europe,[@dkz497-B16]^,^[@dkz497-B17] and many other countries worldwide, for the treatment of various serious infections caused by susceptible Gram-negative bacteria. The safety profile of ceftazidime/avibactam across infection types is consistent with the established safety profile of ceftazidime monotherapy, with the addition of avibactam resulting in no clinically relevant safety differences.[@dkz497-B16]^,^[@dkz497-B17] In contrast to ceftazidime/avibactam and the newer β-lactam/β-lactamase inhibitors, the combination of avibactam with aztreonam restores the *in vitro* activity and *in vivo* efficacy (in preclinical models) of aztreonam against MBL-producing pathogens via inhibition of coexpressed serine β-lactamases,[@dkz497-B18] making it a unique potential treatment option.

A Phase 1, randomized, double-blind study (NCT01689207) showed aztreonam/avibactam to be generally well tolerated, with no evidence of drug--drug interaction between aztreonam and avibactam in healthy subjects, and identified a dosing regimen for further evaluation.[@dkz497-B22]

The current Phase 2a study (REJUVENATE) was the first study of aztreonam/avibactam in a representative population of patients with cIAI, with the aim of selecting the dose regimen for the Phase 3 aztreonam/avibactam development programme. Metronidazole was coadministered with aztreonam/avibactam to provide coverage for anaerobic organisms. The primary objectives were to investigate the pharmacokinetics (PK) and safety of aztreonam/avibactam in patients with cIAI. Assessment of clinical efficacy was a secondary objective.

The study is the first interventional clinical trial conducted within the Innovative Medicines Initiative (IMI)-supported Combatting Bacterial Resistance in Europe - Carbapenem Resistance (COMBACTE-CARE) project. IMI is a joint undertaking between the EU and the European Federation of Pharmaceutical Industries and Associations (EFPIA). COMBACTE-CARE is a consortium of 19 academic and 3 pharmaceutical partners focusing on carbapenem resistance in Europe with the aim of increasing the efficiency of antimicrobial drug development.

Patients and methods
====================

Ethics
------

The study was conducted in compliance with the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice Guidelines. The study protocol was approved by the relevant Institutional Review Boards and/or Independent Ethics Committees at each study site: CPP sud-ouest et Outre-Mer IV, Cabanis Haut---Centre hospitalier Esquirol, Limoges, France (CPP16-006); Universitaet zu Koeln---Geschaeftsstelle Ethikkommission, Cologne, Germany (15-451); CEI de los Hospitales Universitarios Virgen Macarena y Virgen del Rocío, Seville, Spain. All patients provided written informed consent. If patients were unable to provide informed consent at screening, they could be entered into the study by their guardian or legal representative (if in accordance with national and local regulations and as approved by the institution-specific guidelines) and provide their own written informed consent for continuing to participate in the study as soon as possible on recovery.

Study design and patients
-------------------------

REJUVENATE was a prospective, open-label, single-arm, multicentre study (NCT02655419; EudraCT: 2015-002726-39). Eligible patients were aged 18--90 years with a diagnosis of cIAI and a requirement for surgical intervention within 24 h prior to or after initiation of study treatment. A full list of inclusion and exclusion criteria for the study can be found in Text S1 (available as [Supplementary data](#sup1){ref-type="supplementary-material"} at *JAC* Online). Initially, only patients with creatinine clearance (CL~CR~) \>50 mL/min (estimated using the Cockcroft--Gault formula) were eligible for enrolment (Cohort 1). A planned review of all available safety and PK data, by the Scientific Advisory Committee (SAC), occurred once the first 10 patients in Cohort 1 had completed all scheduled assessments. Enrolment was paused during this review. The SAC made recommendations regarding the ongoing conduct of the study. A protocol amendment (see below) broadened the inclusion criteria for Cohorts 2 and 3 to also include patients with CL~CR~ of 31--50 mL/min, with provision for an appropriately adjusted dosing regimen and incorporated a second SAC review of safety and PK data from Cohort 2.

Treatments
----------

Patients were enrolled into three sequential cohorts. Dosage regimens are shown in Table [1](#dkz497-T1){ref-type="table"}. Aztreonam/avibactam dosage regimen for Cohort 1 was supported by population PK modelling and based on the final dosage regimen evaluated in the Phase 1 study by Edeki *et al*.[@dkz497-B22] The population PK model was used in Monte Carlo simulations to select a dosing regimen that achieved a joint PTA for aztreonam and avibactam of \>90%. The joint PTA was based on PK/pharmacodynamic (PD) targets of free (unbound) concentrations of aztreonam exceeding an MIC of 8 mg/L for ≥60% of a dosing interval (≥60% *fT*~\>MIC~) and free concentrations of avibactam exceeding a threshold concentration (CT) of 2.5 mg/L for ≥50% of a dosing interval (≥50% *f*T~\>CT~). The PK/PD targets and joint PTA for aztreonam and avibactam are reported separately.[@dkz497-B23]

###### 

Dosing regimen for each cohort and renal function group

  Cohort and CL~CR~ threshold               Aztreonam/avibactam loading dose (30 min IV infusion)               Aztreonam/avibactam extended loading dose               Aztreonam/avibactam maintenance infusion (3 h IV infusion q6h   Metronidazole (1 h IV infusion q8h)
  ---------------------------------------- ------------------------------------------------------- ------------------------------------------------------------------- --------------------------------------------------------------- -------------------------------------
  Cohort 1 (CL~CR~ \>50 mL/min)                                  500/137 mg                                                  not applicable                                    1500/410 mg[^a^](#tblfn1){ref-type="table-fn"}                         500 mg
  Cohorts 2 and 3 (CL~CR~ \>50 mL/min)                           500/167 mg                                                  not applicable                                    1500/500 mg[^a^](#tblfn1){ref-type="table-fn"}                         500 mg
  Cohorts 2 and 3 (CL~CR~ 31--50 mL/min)                         500/167 mg                         1500/500 mg by 3 h IV infusion[^b^](#tblfn2){ref-type="table-fn"}           750/250 mg[^b^](#tblfn2){ref-type="table-fn"}                         500 mg

First maintenance dose administered immediately after completion of loading dose.

Extended loading dose administered immediately after completion of loading dose; first maintenance dose administered 3 h after completion of extended loading dose.

Population PK modelling, simulation and PTA analyses indicated that an increase in the avibactam component of the regimen optimizes joint PTA \>90% at an MIC of 8 mg/L.[@dkz497-B23] In addition, dose regimens were proposed for patients with CL~CR~ of 31--50 mL/min. A protocol amendment therefore provided options for an optimized (i.e. 500 mg q6h avibactam) dosing regimen, as well as exposure-equivalent regimens for patients with CL~CR~ of 31--50 mL/min and a revised discontinuation criterion (CL~CR~ ≤30 mL/min). Selection of the dosing regimen used in Cohorts 2 and 3 was subject to recommendations from the SAC, following planned interim reviews of safety and PK data from Cohorts 1 and 2. Patients in Cohort 2 subsequently received aztreonam/avibactam at the 1500/500 mg q6h avibactam regimen, with Cohort 3 as an extension cohort at this same dose.

For all cohorts, the planned duration of IV treatment with aztreonam/avibactam (plus IV metronidazole for anaerobic coverage) was 5--14 days. If patients had shown significant clinical improvement after a minimum of 5 days IV therapy, all study treatments could be discontinued at the discretion of the investigator. Daily estimation of CL~CR~ was required during treatment to guide appropriate dose adjustment or discontinuation.

Assessments
-----------

### PK

Blood samples for plasma concentration analysis of aztreonam and avibactam were collected at predefined sampling times on Day 1 and on Day 4 (±1 day). All patients underwent sparse PK sampling (four samples/patient) on Day 1. On Day 4 (±1 day), the first 25 patients enrolled were to undergo intensive PK sampling (11 samples/patient). The remaining 15 patients were to undergo sparse PK sampling on Day 4 (±1 day). Samples were drawn from the opposite arm to that which was used for drug infusions if possible. A central venous catheter (CVC) could be used if peripheral sampling was not possible and a CVC was required for clinical reasons. Aztreonam and avibactam plasma concentrations were determined by Covance Bioanalytical Laboratory (Harrogate, UK) using validated LC--MS/MS methods (described in Text S1). The lower limit of quantification was 0.1 μg/mL for aztreonam and 10 ng/mL for avibactam. Aztreonam and avibactam PK parameters were calculated for each patient with intensive plasma sampling collected on Day 4 (±1 day) using non-compartmental analysis of concentration--time data (Phoenix^®^ WinNonlin 6.4; Certara L.P., St Louis, Missouri, USA).

### Safety

The number, causality and severity of adverse events (AEs) were monitored throughout the study, from screening (Visit 1) until the late follow-up (LFU) visit (Day 35 ± 3 days). Vital signs were assessed at screening, at baseline (Visit 2), daily during treatment, at the end of treatment (EOT), at the test-of-cure (TOC) visit (Day 25 ± 3 days) and at LFU. A complete physical examination was performed at screening, EOT, TOC and LFU visits. ECGs were performed in triplicate on each occasion at baseline (prior to dosing), twice on Day 3 and once at EOT. Hepatic enzymes and renal function \[AST, ALT, alkaline phosphatase (ALP), GGT, total bilirubin and CL~CR~\] were closely monitored throughout the treatment period and intensified monitoring of liver-related laboratory parameters initiated when specific safety criteria were attained (details provided in Text S1).

### Efficacy

Assessments included the number and percentage of patients with investigator-determined clinical cure, clinical failure and indeterminate outcomes at the EOT, TOC and LFU visits (criteria for outcomes shown in Table [S1](#sup1){ref-type="supplementary-material"}).

### Microbiological samples

Specimen collection and culture of isolates for determination of pathogens are described in Text S1.

Statistical methods
-------------------

Up to 40 patients were to be enrolled. Although the study was not powered to perform statistical tests, assessment of safety and complete PK assessments from at least 30 patients with cIAI were considered adequate to confirm the safety and PK profile of aztreonam/avibactam in a population with a representative burden of disease.

PK were analysed for all patients with ≥1 plasma concentration data assessment available, no fundamental violations of the study enrolment criteria, or protocol violations affecting assessment of PK (PK population). Safety was analysed for the modified ITT (MITT) population, which included all enrolled patients who received any amount of study drug. Efficacy was analysed for the MITT population and the microbiologically MITT (mMITT) population, which included all enrolled patients who had a diagnosis of cIAI and had ≥1 intra-abdominal pathogen isolated at baseline, regardless of susceptibility to aztreonam/avibactam.

Descriptive statistics were used to summarize PK, safety and efficacy continuous variables.

Role of the funding source
--------------------------

The academic and EFPIA IMI-supported COMBACTE-CARE consortium partners were involved in: study design; data collection, analysis and interpretation; and data checking of information provided in the article. Responsibility for opinions, conclusions and data interpretation lies with the authors. All authors had full access to all study data and final responsibility for the decision to submit for publication.

Results
=======

Patients
--------

Between 19 May 2016 and 26 October 2017, 40 patients were enrolled across 11 centres located in France, Germany and Spain and, of these, 34 received treatment and thus comprised the MITT population (Cohort 1, *n = *16; Cohorts 2 and 3, *n = *18); patient disposition is shown in Figure [1](#dkz497-F1){ref-type="fig"}. Primary diagnosis relating to appendiceal perforation or peri-appendiceal abscess was at a frequency of 41.2% (Table [2](#dkz497-T2){ref-type="table"}). Only one patient (Cohorts 2 and 3) had CL~CR~ of 31--50 mL/min at baseline. However, this patient, who had acquired acute kidney injury prior to study inclusion, was withdrawn from study treatment on Day 2, owing to further deterioration in renal function meeting the discontinuation criterion. Patient demographics and baseline characteristics were generally well balanced across cohorts (Table [2](#dkz497-T2){ref-type="table"}).

![Patient flow diagram.](dkz497f1){#dkz497-F1}

###### 

Patient demographics and baseline characteristics, including cIAI diagnosis (MITT population)

                                                                                                                                                             Patients, *n* (%)                             
  ---------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------- ---------------------- ----------------------
  Age (years)                                                                                                                                                                                              
   \<65                                                                                                                                                      13 (81.3)              13 (72.2)              26 (76.5)
   65--74                                                                                                                                                    3 (18.8)               5 (27.8)               8 (23.5)
   median (range)                                                                                                                                            49.0 (31--70)          55.5 (19--71)          51.5 (19--71)
  Sex                                                                                                                                                                                                      
   male                                                                                                                                                      12 (75.0)              14 (77.8)              26 (76.5)
   female                                                                                                                                                    4 (25.0)               4 (22.2)               8 (23.5)
  Race                                                                                                                                                                                                     
   white                                                                                                                                                     13 (81.3)              17 (94.4)              30 (88.2)
   native Hawaiian or other Pacific Islander                                                                                                                 1 (6.3)                0                      1 (2.9)
   other                                                                                                                                                     1 (6.3)                0                      1 (2.9)
   unknown                                                                                                                                                   1 (6.3)                1 (5.6)                2 (5.9)
  Ethnicity                                                                                                                                                                                                
   Hispanic or Latino                                                                                                                                        11 (68.8)              14 (77.8)              25 (73.5)
   not Hispanic or Latino                                                                                                                                    5 (31.3)               4 (22.2)               9 (26.5)
  CL~CR~, mL/min, median (range)                                                                                                                             96.5 (54.1--165.0)     110.1 (40.2--182.4)    107.7 (40.2--182.4)
  Height, cm, median (range)                                                                                                                                 170.0 (158.0--182.0)   168.0 (151.0--185.0)   168.5 (151.0--185.0)
  Weight, kg, median (range)                                                                                                                                 82.5 (60.0--120.0)     79.0 (55.0--100.0)     80.0 (55.0--120.0)
  BMI, kg/m^2^, median (range)                                                                                                                               26.0 (19.6--44.1)      27.3 (17.3--31.5)      26.5 (17.3--44.1)
  Diagnosis of cIAI                                                                                                                                                                                        
   acute gastric and duodenal perforations (operated on \>24 h after perforation)                                                                            0                      1 (5.6)                1 (2.9)
   appendiceal perforation or peri-appendiceal abscess                                                                                                       7 (43.8)               7 (38.9)               14 (41.2)
   cholecystitis with gangrenous perforation or progression of the infection beyond the gallbladder wall                                                     2 (12.5)               5 (27.8)               7 (20.6)
   diverticular disease with perforation or abscess                                                                                                          3 (18.8)               1 (5.6)                4 (11.8)
   intra-abdominal abscess (including of liver or spleen provided  that there was extension beyond the organ with evidence of intraperitoneal involvement)   0                      3 (16.7)               3 (8.8)
   secondary peritonitis (but not spontaneous bacterial peritonitis associated with cirrhosis and chronic ascites                                            4 (25.0)               1 (5.6)                5 (14.7)

Values are displayed as *n* (%), unless specified otherwise.

PK
--

Four patients (three in Cohort 1 and one in Cohorts 2 and 3) did not complete intensive PK sampling as planned on Day 4, due to early discontinuation of study treatment; therefore, 21 of the planned 25 patients underwent intensive PK sampling.

Plasma concentration--time profiles of aztreonam and avibactam following infusion of aztreonam/avibactam on Day 4 are summarized in Figure [2](#dkz497-F2){ref-type="fig"}. Table [3](#dkz497-T3){ref-type="table"} provides a summary of observed PK parameters. On Day 4, geometric mean (geometric coefficient of variance, CV%) steady-state aztreonam area under the plasma concentration--time curve (AUC~0--6~) was 235.2 μg·h/mL (60.6%) in Cohort 1 and 234.7 μg·h/mL (54.6%) in Cohorts 2 and 3 (Table [3](#dkz497-T3){ref-type="table"}), whereas that of avibactam was 40.4 μg·h/mL (74.0%) in Cohort 1 and 47.5 μg·h/mL (79.2%) in Cohorts 2 and 3 (Table [3](#dkz497-T3){ref-type="table"}). *C*~max~ of both aztreonam and avibactam generally occurred close to the end of infusion (Table [3](#dkz497-T3){ref-type="table"}). Plasma concentrations of both aztreonam and avibactam at predose and 6 h were similar, indicating that steady-state was attained by Day 4 of the maintenance dose regimen (Figure [2](#dkz497-F2){ref-type="fig"}). PK parameters of both aztreonam and avibactam were similar between avibactam dose groups, with the exception that avibactam AUC~0--6~ was higher in Cohorts 2 and 3 than in Cohort 1 in proportion to the increased avibactam dose (Table [3](#dkz497-T3){ref-type="table"}).

![Mean (±SD) plasma concentration--time curves for aztreonam (a) and avibactam (b) following 3 h IV infusion of aztreonam/avibactam on Day 4, intensive PK sampling.](dkz497f2){#dkz497-F2}

###### 

Summary of steady-state aztreonam and avibactam PK parameters following IV infusion of aztreonam/avibactam

  PK parameter            Cohort 1 (*n = *16)   Cohort 2 + 3 (*n = *18)
  ----------------------- --------------------- -------------------------
  *Aztreonam*                                   
  AUC~0--6~ (μg·h/mL)                           
  *  n*                   13                    8
  * * geometric mean      235.2                 234.7
  * * CV (%)              60.6                  54.6
  *C* ~max~ (μg/mL)                             
  *  n*                   13                    8
  * * geometric mean      62.5                  55.4
  * * CV (%)              146.9                 42.6
  *T* ~max~ (h)                                 
  *  n*                   13                    8
  * * median              2.9                   2.4
  * * (min--max)          0.5--3.5              2.0--3.0
  *t* ~½~ (h)                                   
  *  n*                   11                    8
  * * mean (SD)           2.3 (1.06)            2.8 (2.05)
  CL (L/h)                                      
  *  n*                   13                    8
  * * geometric mean      6.4                   6.4
  * * CV (%)              35.4                  35.5
  *V* ~ss~ (L)                                  
  *  n*                   11                    8
  * * geometric mean      20.3                  19.6
  * * CV (%)              16.9                  31.8
  *V* ~z~ (L)                                   
  *  n*                   11                    8
  * * geometric mean      21.4                  21.6
  * * CV (%)              15.3                  24.1
  *Avibactam*                                   
  AUC~0--6~ (μg·h/mL)                           
  *  n*                   13                    8
  * * geometric mean      40.4                  47.5
  * * CV (%)              74.0                  79.2
  *C* ~max~ (μg/mL)                             
  *  n*                   13                    8
  * * geometric mean      11.6                  12.1
  * * CV (%)              164.5                 61.2
  *T* ~max~ (h)                                 
  *  n*                   13                    8
  * * median (min--max)   2.9 (0.5--3.8)        2.8 (2.0--3.3)
  *t* ~½~ (h)                                   
  *  n*                   11                    8
  * * mean (SD)           1.8 (0.59)            2.2 (1.85)
  CL (L/h)                                      
  *  n*                   13                    8
  * * geometric mean      10.1                  10.5
  * * CV (%)              42.6                  41.4
  *V* ~ss~ (L)                                  
  *  n*                   11                    8
  * * geometric mean      26.0                  23.7
  * * CV (%)              22.0                  29.7
  *V* ~z~ (L)                                   
  *  n*                   11                    8
  * * geometric mean      28.2                  27.4
  * * CV (%)              20.4                  20.6

*V* ~z~, volume of distribution during the terminal phase after IV administration.

Safety
------

A total of 55 treatment-emergent AEs were reported in 23 (67.6%) patients overall, \[11 (68.8%) in Cohort 1; 12 (66.7%) in Cohorts 2 and 3; Table [4](#dkz497-T4){ref-type="table"}\]. The most common AE \[Medical Dictionary for Regulatory Activities (MedDRA) preferred term\] was 'hepatic enzyme increased', occurring in nine (26.5%) patients \[seven (43.8%) in Cohort 1 and two (11.1%) in Cohorts 2 and 3\]. Of these nine cases, seven (20.6%) were considered related to aztreonam/avibactam, one was related to metronidazole and one was not drug-related. The onset of these AEs ranged from Day 4 to Day 17 (Table [S2](#sup1){ref-type="supplementary-material"}). All cases were mild or moderate in severity.

###### 

Summary of treatment-emergent AEs, treatment-emergent AEs occurring in ≥2 patients and SAEs, by system organ class and preferred term (MITT population)

  Characteristic                                                               Cohort 1 (*n = *16)   Cohorts 2 + 3 (*n = *18)   Total (*N = *34)
  ---------------------------------------------------------------------------- --------------------- -------------------------- --------------------------------------------
  Patients with any AE                                                         11 (68.8)             12 (66.7)                  23 (67.6)
  Patients with outcome of death (related and not related)                     0                     1 (5.6)                    1 (2.9)[^a^](#tblfn5){ref-type="table-fn"}
  Patients with SAEs                                                           4 (25.0)              5 (27.8)                   9 (26.5)
  Patients discontinued from study drug due to AEs and continued study         2 (12.5)              2 (11.1)                   4 (11.8)
  Any AE with severe intensity                                                 3 (18.8)              2 (11.1)                   5 (14.7)
  Any AE related to aztreonam/avibactam                                        8 (50.0)              2 (11.1)                   10 (29.4)
  Any AE related to metronidazole                                              1 (6.3)               0                          1 (2.9)
  AEs by system organ class/MedDRA preferred term, *n* (%)                                                                      
    blood and lymphatic system disorders                                       2 (12.5)              2 (11.1)                   4 (11.8)
     anaemia                                                                   1 (6.3)               2 (11.1)                   3 (8.8)
    gastrointestinal disorders                                                 3 (18.8)              8 (44.4)                   11 (32.4)
     abdominal pain lower                                                      0                     2 (11.1)                   2 (5.9)
     diarrhoea                                                                 2 (12.5)              3 (16.7)                   5 (14.7)
     nausea                                                                    0                     2 (11.1)                   2 (5.9)
    general disorders/administration site conditions                           1 (6.3)               2 (11.1)                   3 (8.8)
     oedema                                                                    0                     2 (11.1)                   2 (5.9)
  Investigations                                                               7 (43.8)              2 (11.1)                   9 (26.5)
    hepatic enzyme increased                                                   7 (43.8)              2 (11.1)                   9 (26.5)
  SAEs by system organ class/MedDRA preferred term, *n* (%)                                                                     
    patients with any SAE                                                      4 (25.0)              5 (27.8)                   9 (26.5)
    gastrointestinal disorders                                                 0                     2 (11.1)                   2 (5.9)
     intra-abdominal haematoma                                                 0                     1 (5.6)                    1 (2.9)
     pancreatitis acute                                                        0                     1 (5.6)                    1 (2.9)
    infections and infestations                                                2 (12.5)              0                          2 (5.9)
     abdominal wall infection                                                  1 (6.3)               0                          1 (2.9)
     sepsis                                                                    1 (6.3)               0                          1 (2.9)
    injury, poisoning and procedural complications                             0                     2 (11.1)                   2 (5.9)
    arterial injury                                                            0                     1 (5.6)                    1 (2.9)
     postoperative ileus                                                       0                     1 (5.6)                    1 (2.9)
    neoplasms benign, malignant and unspecified (including cysts and polyps)   1 (6.3)               0                          1 (2.9)
     colon cancer                                                              1 (6.3)               0                          1 (2.9)
    renal and urinary disorders                                                0                     1 (5.6)                    1 (2.9)
     acute kidney injury                                                       0                     1 (5.6)                    1 (2.9)
    respiratory, thoracic and mediastinal disorders                            2 (12.5)              0                          2 (5.9)
     acute respiratory distress syndrome                                       1 (6.3)               0                          1 (2.9)
     respiratory distress                                                      1 (6.3)               0                          1 (2.9)
    skin and subcutaneous tissue disorders                                     0                     1 (5.6)                    1 (2.9)
     haemorrhage, subcutaneous                                                 0                     1 (5.6)                    1 (2.9)

This event was a post-LFU event. Values are displayed as *n* (%).

The second most frequent treatment-emergent AE was diarrhoea, occurring in five (14.7%) patients. All cases were of mild severity and not considered related to aztreonam/avibactam or due to *Clostridioides difficile* infection*.* Thrombocytosis occurred in six (17.6%) patients who met predefined potentially clinically significant (PCS) criteria \[platelets \>1.5 × upper limit of normal (ULN) and \>100% increase from baseline\]. Possible alternative aetiologies were evident in five of these cases and no patient reported a thrombotic event.

Ten AEs considered to be treatment-related were reported in eight patients in Cohort 1 (seven AEs of 'hepatic enzyme increased', one of visual hallucinations, one of thrombocytosis and one of hepatitis) and two patients in Cohorts 2 and 3 (one AE each of 'hepatic enzyme increased').

Serious AEs (SAEs) were reported in a total of nine (26.5%) patients \[Cohort 1, *n = *4; Cohorts 2 and 3, *n = *5 (Table [4](#dkz497-T4){ref-type="table"})\]. None was considered treatment-related. Four patients (11.8%) were discontinued from the study drug owing to AEs, of which three were due to liver enzyme disorders (two of these were 'hepatic enzyme increased' and considered treatment-related and one was an event of hypertransaminasaemia that was assessed as being unrelated to the study drug). The fourth was a patient with worsening of kidney failure unrelated to the study drug.

PCS increases in ALT and/or AST (\>3 × ULN and 100% change from baseline), based on laboratory assessment alone, were identified in six patients \[17.6%; two patients in Cohort 1 (one patient with AE report of 'hepatic enzyme increased' and one with AE of hepatitis) and four in Cohorts 2 and 3 (one patient with AE of 'hepatic enzyme increased', one with an SAE of postoperative ileus, one with SAE of arterial injury and one with SAEs of acute pancreatitis and intra-abdominal haematoma and an AE of hypertransaminasaemia)\]. The majority of increases resolved rapidly following discontinuation of treatment. However, for the patient with postoperative ileus, ALT levels remained 2 × ULN on Day 43 at an unscheduled visit after the LFU visit. The subject remained asymptomatic of hepatic injury throughout and the event did not require treatment. Two of the six patients with PCS increases in transaminases also experienced PCS increases in total bilirubin (\>1.5 × ULN and 100% change from baseline). In both cases, alternative aetiologies were evident (thrombosis of left suprahepatic vein/hepatic artery injury and acute pancreatitis). There were no confirmed Hy's law cases (definition of Hy's criteria provided in Text S1).

No deaths occurred during the AE collection period defined in the protocol. Two fatal events were reported, one prior to the patient receiving study treatment and one which occurred 1 week after the LFU visit, when the patient was no longer taking part in the study. Both cases were assessed as not related to study treatment.

Assessment and medical monitoring/review of vital sign and ECG data did not reveal any clinically relevant abnormalities attributed to aztreonam/avibactam.

Efficacy
--------

Investigator assessment of clinical response at EOT and TOC is summarized in Table [5](#dkz497-T5){ref-type="table"}. Overall, 67.6% and 73.9% of patients experienced clinical cure at EOT in the MITT and mMITT populations, respectively. Approximately 60% of patients overall were assessed as being cured at TOC (58.8% in the MITT population and 60.9% in the mMITT population).

###### 

Investigator assessment of clinical responses at the EOT and TOC visits (MITT and mMITT populations)

  Timepoint/response   Cohort 1                       Cohorts 2 + 3                  Total
  -------------------- ------------------------------ ------------------------------ --------------
  *EOT*                                                                              
    MITT population    *n* *=* *16*                   *n* *=* *18*                   *N* *=* *34*
     cure              10 (62.5)                      13 (72.2)                      23 (67.6)
     failure           3 (18.8)                       4 (22.2)                       7 (20.6)
     indeterminate     2 (12.5)                       0                              2 (5.9)
    mMITT population   *n* *=* *12*                   *n* *=* *11*                   *N* *=* *23*
     cure              8 (66.7)                       9 (81.8)                       17 (73.9)
     failure           2 (16.7)                       1 (9.1)                        3 (13.0)
     indeterminate     1 (8.3)                        0                              1 (4.3)
  *TOC*                                                                              
    MITT population    *n* *=* *16*                   *n* *=* *18*                   *N* *=* *34*
     cure              10 (62.5), 95% CI 35.4--84.8   10 (55.6), 95% CI 30.8--78.5   20 (58.8)
     failure           3 (18.8)                       5 (27.8)                       8 (23.5)
     indeterminate     3 (18.8)                       3 (16.7)                       6 (17.6)
    mMITT population   *n* *=* *12*                   *n* *=*  *11*                  *N* *=* *23*
     cure              8 (66.7), 95% CI 34.9--90.1    6 (54.5), 95% CI 23.4--83.3    14 (60.9)
     failure           2 (16.7)                       2 (18.2)                       4 (17.4)
     indeterminate     2 (16.7)                       3 (27.3)                       5 (21.7)

Some patients did not have a clinical response assessment at one or more visits. Values shown are *n* (%).

Baseline pathogens
------------------

In total, 23/34 (67.6%) patients had a pathogen identified at baseline and comprised the mMITT population. *E. coli*, *Klebsiella pneumoniae* and *Klebsiella oxytoca* were the most commonly isolated Enterobacteriaceae species (Table [S3](#sup1){ref-type="supplementary-material"}). Nine of these 23 (39.1%) patients had a single pathogen isolated and 14/23 (60.9%) had more than one pathogen isolated. The baseline pathogen profile was balanced across cohorts and consistent with the cIAI population. The individual aztreonam/avibactam MIC distributions for all baseline pathogens (aerobes) in the mMITT population are displayed in Table [S4](#sup1){ref-type="supplementary-material"}.

Discussion
==========

REJUVENATE is the first study of aztreonam/avibactam in patients with a representative burden of infection and, as such, represents an important clinical milestone. PK and safety of aztreonam/avibactam were evaluated in patients with cIAI using dosing regimens selected to achieve PK/PD targets based on preclinical and healthy volunteer PK data. Following review of safety/tolerability and PK assessments in Cohort 1, the avibactam component of the combined dose was increased to optimize target attainment based on an updated population PK/PD model and target attainment rate estimations.[@dkz497-B23]

Aztreonam/avibactam is one of the few treatments in clinical development specifically designed to target serious infections caused by MBL-producing Enterobacteriaceae, particularly those harbouring other β-lactamases, such as ESBLs. This study forms part of a streamlined development programme being pursued for aztreonam/avibactam, driven by the lack of effective treatment options and the prior preclinical and clinical experience with both aztreonam and avibactam.[@dkz497-B12]^,^[@dkz497-B16]^,^[@dkz497-B17]

The steady-state mean clearance of aztreonam in patients with cIAI was similar compared with healthy volunteers who received similar dosing regimens \[6.4 L/h versus 5.3--7.4 L/h, respectively (NCT01689207)\]. Clearance of avibactam was somewhat lower in cIAI, versus healthy volunteers (10.1--10.5 L/h versus 10.3--15.5 L/h, respectively). Mean aztreonam and avibactam apparent volume of distribution at steady-state after IV administration in patients with cIAI was modestly higher than the mean values reported in young adult healthy volunteers. This was not unexpected in patients with acute IAI and recent surgery, as distribution may be affected by changes in blood volume, circulation, extracellular fluid and circulating plasma protein levels.[@dkz497-B24] Exposures of aztreonam and avibactam achieved in patients with cIAI were consistent with the predicted exposures for both avibactam dose regimens based on the updated population PK models.[@dkz497-B23]

Importantly, the PK results for aztreonam and avibactam reported here confirm that the dosing regimen studied in Cohorts 2 and 3 is appropriate for the Phase 3 programme.

Aztreonam/avibactam was generally well tolerated and the pattern of reported AEs resembles those observed in the ceftazidime/avibactam clinical development programme, which also used additional metronidazole in patients with cIAI.[@dkz497-B16]^,^[@dkz497-B17]^,^[@dkz497-B25]

In line with the hepatic safety profile of aztreonam monotherapy,[@dkz497-B12] drug-induced liver injury effects were expected and liver parameters were therefore monitored. AEs of 'hepatic enzyme increased' were reported in nine (26.5%) patients overall. Most of these AEs concerned asymptomatic transaminase elevations in patients in Cohort 1, the majority of which did not meet potentially clinically significant criteria based on laboratory parameter assessment and none of which met Hy's law criteria.

Procedural injuries to the liver, or medical history, such as diabetes, steatosis, cholelithiasis or chronic hepatitis C, may have contributed to the occurrence of transaminase elevations; severe cIAI, surgery and anaesthetics can also result in increases in liver enzymes.[@dkz497-B26] In addition, most patients received concomitant medications, such as paracetamol or additional antibiotics, which are known to have potential effects on the liver.[@dkz497-B29]

Of note, elevations in liver transaminases associated with aztreonam are usually reversible with treatment discontinuation and typically occur without overt signs or symptoms of hepatobiliary dysfunction.[@dkz497-B12] This is reflected by the observations in the current study, in which most of the AEs relating to liver enzyme increases were asymptomatic and recovered during the study.

The incidence of diarrhoea was slightly higher than the safety profile presented in the aztreonam summary of product characteristics (SmPC);[@dkz497-B12] it is difficult to assess whether this is due to a true increase in incidence or underlying intra-abdominal pathology. The increase in occurrence of diarrhoea is not considered to be of clinical significance, as events were mild and mostly resolved before the LFU visit. None were related to *C. difficile.* Nevertheless, the finding should be investigated further in future studies.

In the current study, approximately 60% of patients with cIAI attained clinical cure at TOC. Although enrolment was opened to patients with CL~CR~ of 31--50 mL/min in Cohorts 2 and 3, the assessment of aztreonam/avibactam in such patients was limited by the fact that only one patient with baseline CL~CR~ \<50 mL/min was enrolled. This patient discontinued on Day 2 and had no evaluable PK data available for analysis. MDR bacteria are emerging with increasing incidence worldwide and effective antibiotic medication is often limited or unavailable, resulting in increased morbidity and mortality.[@dkz497-B1] Although currently rare in most parts of Europe, outbreaks due to CRE, including MBL, have the potential to be severe and have been reported in various EU countries.[@dkz497-B30] Overall, the findings strongly support further development of aztreonam/avibactam; although, as no MBL- or ESBL-producing bacteria were detected in the isolates from the 34 patients in the present study, the contribution of avibactam in the aztreonam/avibactam combination to *in vivo* efficacy in this subgroup of species could not be evaluated and further studies are therefore needed to investigate this aspect of the study drug combination.

In summary, the PK data for aztreonam and avibactam in cIAI patients reported here confirm that the aztreonam/avibactam 500/167 mg (30 min infusion) loading dose and 1500/500 mg (3 h infusions) maintenance dose q6h dosing regimen, in patients with CL~CR~ \>50 mL/min, is appropriate for the Phase 3 development programme. The overall safety profile of aztreonam/avibactam is in line with that of aztreonam alone, with a favourable risk--benefit profile. Results from this study support the clinical development of aztreonam/avibactam.

Supplementary Material
======================

###### 

Click here for additional data file.
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